Lebrikizumab in Uncontrolled Asthma: Reanalysis in a Well-Defined Type 2 Population

By sjmartinez • February 16, 2024

Corren J, Szefler SJ, Sher E, Korenblat P, Soong W, Hanania NA, Berman G, Brusselle G, Zitnik R, Natalie CR, Sun L, Siu K, Wu WS, Lio P, Armstrong AW. Lebrikizumab in Uncontrolled Asthma: Reanalysis in a Well-Defined Type 2 Population. J Allergy Clin Immunol Pract. 2024 Feb 13:S2213-2198(24)00163-6. doi: 10.1016/j.jaip.2024.02.007. Epub ahead of print. PMID: 38360213.

Tags: Allergic asthma, Dermatology, efficacy, IL-13, lebrikizumab, post-hoc analysis, Publications, safety

Peterson H, Miao KL, Huang MY, Armstrong AW. Trending Psychiatric Comorbidities in Patients with Alopecia Areata in the United States from 2002 to 2019. J[...]

Biomarkers in Atopic Dermatitis: A Review of the Role of IL-13 and the Impact of Tralokinumab Treatment

Gorelick J, Nguyen A, Schneider SKR, Martel BC, Madsen DE, Armstrong AW. Biomarkers in Atopic Dermatitis: A Review of the Role of IL-13 and the[...]

Tapinarof Improved Outcomes and Sleep for Patients and Families in Two Phase 3 Atopic Dermatitis Trials in Adults and Children

Simpson EL, Hebert AA, Browning J, Serrao RT, Sofen H, Brown PM, Piscitelli SC, Rubenstein DS, Tallman AM. Tapinarof Improved Outcomes and Sleep for Patients[...]